Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a

NCT02646371 is registered in ClinicalTrials.gov with LimmaTech Biologics AG as lead sponsor.

NCT NCT02646371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02646371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a
Lead sponsor
LimmaTech Biologics AG
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2015
Completion date
July 31, 2017
Enrollment
67 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

shigellosis